- Sections
- C - Chimie; métallurgie
- C07D - Composés hétérocycliques
- C07D 239/69 - Benzènesulfonamido-pyrimidines
Détention brevets de la classe C07D 239/69
Brevets de cette classe: 91
Historique des publications depuis 10 ans
|
5
|
4
|
5
|
6
|
5
|
7
|
11
|
6
|
4
|
1
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Xenon Pharmaceuticals Inc. | 190 |
7 |
| Vertex Pharmaceuticals Incorporated | 1581 |
5 |
| ESSA Pharma Inc. | 40 |
5 |
| AstraZeneca AB | 3042 |
3 |
| Eastern Virginia Medical School | 80 |
3 |
| Genzyme Corporation | 1205 |
3 |
| The Regents of the University of California, Santa Cruz | 19 |
3 |
| Thomas Jefferson University | 502 |
3 |
| University of Dundee | 194 |
3 |
| ZaCh System S.p.A. | 27 |
3 |
| BASF SE | 19740 |
2 |
| Genentech, Inc. | 3742 |
2 |
| FUJIFILM Corporation | 27102 |
2 |
| Board of Regents, The University of Texas System | 5370 |
2 |
| ADAMA Agan Ltd. | 316 |
2 |
| ADAMA Makhteshim Ltd. | 427 |
2 |
| The Arizona Board of Regents on Behalf of the University of Arizona | 1906 |
2 |
| Generics [UK] Limited | 132 |
2 |
| Sanford-Burnham Medical Research Institute | 128 |
2 |
| The United States of America Department of Health | 2 |
2 |
| Autres propriétaires | 33 |